Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:28 p.m.

    📋 Kiniksa Pharmaceuticals, Ltd. (KNSA) - Financial Results

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 07:35:08

    Event Type: Financial Results

    Event Details:

    Kiniksa Pharmaceuticals (KNSA) Reports Q3 2022 Financial Results Kiniksa Pharmaceuticals (KNSA) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 26972
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 138208
      • targeting GM-CSFRα) ·Kiniksa is evaluating the development of mavrilimumab in rare cardiovascular diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been implicated and that have synergies with the company’s existing commercial infrastructure. Financial Results ·Total net revenue for ARCALYST product sales in the second quarter of 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Costs And Operating Expenses Selling General Administrative 21.85K 46.06K $-24.21K -52.57%
    Costs And Operating Expenses Loss From Operations 40.55K 42.69K $-2.13K -4.99%
    Costs And Operating Expenses Interest Income 6.00 137.00 $-131.00 -95.62%
    Costs And Operating Expenses Net Loss 41.56K 45.19K $-3.63K -8.03%
    Revenue 26.97K 7.70K $19.27K +250.10%
    Selling, General & Administrative 23.84K 21.85K $1.99K +9.12%
    Loss from Operations 19.37K 40.55K $-21.19K -52.24%
    Interest Income 103.00 6.00 $97.00 +1616.67%
    Net Loss 19.98K 41.56K $-21.58K -51.93%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Kiniksa Pharmaceuticals
    • CIK: 0001730430
    • Ticker Symbol: KNSA
    • Period End Date: 2022-08-02
    • Document Type: 8-K

Search

News categories